|
|
Prepublished online as a Blood First Edition Paper on December 27, 2002; DOI 10.1182/blood-2002-09-2908.
 Previous Article | Table of Contents | Next Article 
Blood, 1 May 2003, Vol. 101, No. 9, pp. 3590-3593
IMMUNOBIOLOGY
Brief report
The serine protease granzyme M is preferentially
expressed in NK-cell,   T-cell, and intestinal T-cell lymphomas:
evidence of origin from lymphocytes involved in innate
immunity
Laszlo Krenacs,
Mark J. Smyth,
Eniko Bagdi,
Tibor Krenacs,
Laszlo Kopper,
Thomas Rudiger,
Andreas Zettl,
Hans Konrad Muller-Hermelink,
Elaine S. Jaffe, and
Mark Raffeld
From the Laboratory of Tumor Pathology and Molecular
Diagnostics, Institute for Biotechnology, Bay Zoltan Foundation for
Applied Research, Szeged, Hungary; Division of Cancer Immunology, Peter
MacCallum Cancer Institute, East Melbourne, Victoria,
Australia; 1st Institute of Pathology and Experimental Cancer
Research, Semmelweis University of Medicine, Budapest, Hungary;
Department of Pathology, University of Wurzburg, Germany;
and the Specialized Diagnostics Unit and Hematopathology Section,
Laboratory of Pathology, National Cancer Institute, National Institutes
of Health, Bethesda, MD.
Granzyme M (GM) is a novel serine protease whose expression
is highly restricted to natural killer (NK) cells,
CD3+CD56+ T cells, and   T cells. Using a
GM-specific monoclonal antibody, we analyzed the expression of GM in
214 mature T-cell and NK-cell lymphomas. GM was preferentially
expressed in nasal NK/T-cell lymphomas (100%), T-cell lymphomas
(100%), and intestinal T-cell lymphomas (85%). In contrast, GM
expression was present at low prevalence in mycosis
fungoides/Sézary syndrome (3%), anaplastic large-cell lymphoma
(6%), panniculitis-like T-cell lymphoma (11%), and angioimmunoblastic
T-cell lymphoma (0%) cases. Peripheral T-cell lymphomas of unspecified
subtype showed an intermediate frequency (37%) of GM expression,
consistent with their heterogeneous origin. We conclude that GM
expression is a distinctive feature of the nasal NK/T-cell,
T-cell, and intestinal T-cell lymphomas, and suggest that these tumors
develop from lymphocytes involved in innate immunity.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Wu, L. Wang, G. Hua, K. Liu, X. Yang, Y. Zhai, M. Bartlam, F. Sun, and Z. Fan
Structural Basis for Proteolytic Specificity of the Human Apoptosis-Inducing Granzyme M
J. Immunol.,
July 1, 2009;
183(1):
421 - 429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bossard, K. Belhadj, F. Reyes, N. Martin-Garcia, F. Berger, J. A. Kummer, J. Briere, A.-C. Baglin, S. Cheze, J. Bosq, et al.
Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials
Blood,
March 1, 2007;
109(5):
2183 - 2189.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Waterhouse, V. R. Sutton, K. A Sedelies, A. Ciccone, M. Jenkins, S. J. Turner, P. I. Bird, and J. A. Trapani
Cytotoxic T lymphocyte-induced killing in the absence of granzymes A and B is unique and distinct from both apoptosis and perforin-dependent lysis.
J. Cell Biol.,
April 10, 2006;
173(1):
133 - 144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Jaffe
Pathobiology of Peripheral T-cell Lymphomas
Hematology,
January 1, 2006;
2006(1):
317 - 322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Bade, H. E. Boettcher, J. Lohrmann, C. Hink-Schauer, K. Bratke, D. E. Jenne, J. C. Virchow Jr, and W. Luttmann
Differential expression of the granzymes A, K and M and perforin in human peripheral blood lymphocytes
Int. Immunol.,
November 1, 2005;
17(11):
1419 - 1428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
